# Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

> **NCT01160484** · PHASE2 · COMPLETED · sponsor: **Oncotherapeutics** · enrollment: 40 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** DVD-R

## Key facts

- **NCT ID:** NCT01160484
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160484, "Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01160484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*